| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 04/15/2009 | CN101406456A Technique for preparing florfenicol soluble powder |
| 04/15/2009 | CN101406453A Pharmaceutical compositions for oral and topical administration |
| 04/15/2009 | CN101406450A Technique for preparing compound amoxicillin oil suspension injection |
| 04/15/2009 | CN101406449A Compound dichlofluanid injection and technique for preparing the same |
| 04/15/2009 | CN101406447A Technique for preparing compound ceftiofur oil suspension injection |
| 04/15/2009 | CN100478439C Prawn antiviral growth-promoting double-function engineering strain, construct method and application |
| 04/15/2009 | CN100478359C Polyethylene glycol-interferon coupler and its preparation method |
| 04/15/2009 | CN100478349C Nucleoside fluoride compound, its production and use |
| 04/15/2009 | CN100478342C Fluorine carbostyrile-oxazolidinone derivative and composition thereof, preparation method and usage |
| 04/15/2009 | CN100478341C Voriconazole derivate and preparation process thereof |
| 04/15/2009 | CN100478030C SARS resisting medicine action target and its preventing and treating medicine |
| 04/15/2009 | CN100478028C Genetic engineering vaccine of enterohemorrhagic escherichia coli O157:H7 and the preparing method thereof |
| 04/15/2009 | CN100478011C Medicament for treating AIDS |
| 04/15/2009 | CN100478006C Chinese traditional medicine preparation for treating acute or chronic hepatitis |
| 04/15/2009 | CN100478004C Chinese medicinal composistion for treating common cold, its preparation method and quality control method |
| 04/14/2009 | US7517998 Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus |
| 04/14/2009 | US7517992 (-)-cis-1-(5-(4-fluorophenoxy)-pyridin-2-yl)-3-(4,7-difluoro-1,1a,2,7b-tetrahydro-cyclopropa[c]chromene-1-yl)-urea; improved resistance and pharmacokinetic profile; polymerase inhibitors; potent against virus comprising drug escape mutations |
| 04/14/2009 | US7517989 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 04/14/2009 | US7517987 Interleukin converting enzyme inhibitors such as 5-Fluoro-4-oxo-3-(2-(6-oxo-6H-pyrimidin-1-yl)-butyrylamino)-pentanoic acid, administered as modulators of cell apoptosis and inflammation |
| 04/14/2009 | US7517976 proteins and/or polypeptides encoded by DNA isolated from rna viruses, used as vaccines, for detection and treatment of swine infected with PRRSV |
| 04/14/2009 | US7517974 Blood coagulation factor; nucleotide sequence encodes polypeptide; amino acid sequence differs in 1-15 amino acid residues and comprises an introduced in vivo N-glycosylation site; substitution V253N; coagulation related disorders |
| 04/14/2009 | US7517965 Non-neutralizing anti-aPC antibodies |
| 04/14/2009 | US7517887 Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof |
| 04/14/2009 | US7517883 Solubilized topoisomerase poisons |
| 04/14/2009 | US7517875 Piperidine derivatives having CCR3 antagonism |
| 04/14/2009 | US7517872 Enzyme inhibitors; interferons; interleukins; cyclosporins; Cycloprop[d]indolo[2,1-a][2]benzazepine/indolo[2,1-a][2]benzazepine derivatives; N'-(5-((sec-Butylsulfonyl)carbamoyl)-8-cyclohexyl-11-methoxy-1,12b-dihydrocyclopropa[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl)-N,N-dimethylethanediamide |
| 04/14/2009 | US7517861 Containing unmethylated CpG dinucleotides; redirection of a Th2 response to a Th1 response; atopic diseases, dermatitis |
| 04/14/2009 | US7517858 Prodrugs of pharmaceuticals with improved bioavailability |
| 04/14/2009 | US7517683 Gene expression of alphavirus; nucleotide sequences; induce immunology response; aids vaccine |
| 04/14/2009 | US7517666 Using urease as tool in identifying modulators of bacterial propagation; enzyme inhibitors |
| 04/14/2009 | US7517661 Methods of screening for ligands for FPRL2 |
| 04/14/2009 | US7517533 Pseudomonas aeruginosa antigens |
| 04/14/2009 | US7517532 Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors |
| 04/14/2009 | US7517531 Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4 |
| 04/14/2009 | US7517517 Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands |
| 04/14/2009 | CA2427817C Estrone-derivatives having cytoprotective activity |
| 04/14/2009 | CA2412213C A method for treating septic shock |
| 04/14/2009 | CA2395016C Treatment of dna viral infections |
| 04/14/2009 | CA2380980C Mutilin derivatives and their use as antibacterials |
| 04/14/2009 | CA2362914C Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections |
| 04/14/2009 | CA2359440C Phenylphenanthridines with pde-iv inhibiting activity |
| 04/14/2009 | CA2269682C Improved pharmaceutical compositions |
| 04/14/2009 | CA2232378C Aerosol compositions |
| 04/14/2009 | CA2221279C Palladium catalyzed nucleoside modification methods using nucleophiles and carbon monoxide |
| 04/09/2009 | WO2009046369A2 Use of a specific dosage regimen of ifn-alpha and ribavirin for treating hepatitis c |
| 04/09/2009 | WO2009046220A2 Lipopeptides for delivery of nucleic acids |
| 04/09/2009 | WO2009046098A1 Novel cyclic boronate inhibitors of hcv replication |
| 04/09/2009 | WO2009045975A1 Potent combinations of zidovudine and drugs that select for the k65r mutation in the hiv polymerase |
| 04/09/2009 | WO2009045952A1 Oral compositions containing botanical extracts |
| 04/09/2009 | WO2009045951A1 Anti-bacterial pyrocatechols and related methods |
| 04/09/2009 | WO2009045706A1 Inhaled aztreonam lysine for the treatment of deficits in health-related quality-of life in lung diseases |
| 04/09/2009 | WO2009045497A1 Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
| 04/09/2009 | WO2009044930A1 Pharmaceutical composition for inhibiting the accumulation of amyloid-β protein |
| 04/09/2009 | WO2009044788A1 Benzoxazinone derivative |
| 04/09/2009 | WO2009044777A1 Oxazolidinone derivative having 7-membered hetero ring |
| 04/09/2009 | WO2009044311A1 Thiophene-2-carboxamide derivatives as modulators of ccr9 receptor |
| 04/09/2009 | WO2009043987A1 Antibiotic compositions containing essential oils, prophylaxis and treatment of nosocomial diseases |
| 04/09/2009 | WO2009043958A1 Use of atomic quantum clusters (aqc) as antimicrobial agents and biocides |
| 04/09/2009 | WO2009043529A1 Thyrotropin releasing hormone for therapeutic applications |
| 04/09/2009 | WO2009043528A1 Substance p and thyrotropin releasing hormone for therapeutic applications |
| 04/09/2009 | WO2009043527A2 Therapeutic use of human growth hormone 1-43 |
| 04/09/2009 | WO2009043526A2 Use of gip ( 6-30) alone or in combination with hgh as a therapeutic agent |
| 04/09/2009 | WO2009043524A2 Use of a peptide as therapeutic agent |
| 04/09/2009 | WO2009043523A2 Cortistatin 17 and neuropeptide 1 for use as therapeutic agent |
| 04/09/2009 | WO2009043522A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043521A2 Use of urocortin iii and urocortin i as therapeutic agents |
| 04/09/2009 | WO2009043520A1 Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents |
| 04/09/2009 | WO2009043519A2 Use of band 3 protein and pacap-27 as a therapeutic agent |
| 04/09/2009 | WO2009043518A2 Use of a combination of cart peptides as a therapeutic agent |
| 04/09/2009 | WO2009043507A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043506A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043505A2 Use of beta-melanotropin as a therapeutic agent, eg for the treatment of aids or alzheimer |
| 04/09/2009 | WO2009043504A2 Use of apelin-36 and optionally beta-melanotropin as therapeutic agents, eg for treating aids or alzheimer |
| 04/09/2009 | WO2009043481A2 Use of adrenomedullin 13-52 and optionally retrocyclin-1 as a therapeutic agent for the treatment of hcmv infections |
| 04/09/2009 | WO2009043480A2 Use of leptin (22-56 ) as a therapeutic agent |
| 04/09/2009 | WO2009043479A2 Use of eaa-mart1 (26-35) for the treatment of human cytomegalovirus infections |
| 04/09/2009 | WO2009043478A2 Use of bubuc and optionally eaa-mart1 (26-35) as a therapeutic agent for the treatment of hcmv infections |
| 04/09/2009 | WO2009043477A2 Use of glpl (7-36) alone or in combination with leptin 22-56 as a therapeutic agent |
| 04/09/2009 | WO2009043476A2 Neuromedin s as a therapeutic agent |
| 04/09/2009 | WO2009043469A2 Use of pneumadin as a therapeutic agent |
| 04/09/2009 | WO2009043468A2 Use of corticotropin-releasing factor as a therapeutic agent |
| 04/09/2009 | WO2009043467A1 U e of urocortin and corticotropin-releasing fact r as therapeutic agents |
| 04/09/2009 | WO2009043466A2 Therapeutic use of the peptide gluten exorphin a5 |
| 04/09/2009 | WO2009043465A2 Use of beta-endorphin as a therapeutic agent |
| 04/09/2009 | WO2009043464A2 Astressin and beta- endorphin for use as therapeutic agents |
| 04/09/2009 | WO2009043462A1 Use of neuropeptide af as a therapeutic agent |
| 04/09/2009 | WO2009043461A1 Use of a hnp-1 defensin peptide, alone or in combination with neuropeptide af, as a therapeutic agent |
| 04/09/2009 | WO2009043460A1 Use of alpha-endorphin as a therapeutic agent |
| 04/09/2009 | WO2009043459A1 Use of a platelet fibrinogen receptor hexapeptide antagonist and alpha-endorphin as therapeutic agents |
| 04/09/2009 | WO2009043458A2 Use of oxytocin to treat many diseases |
| 04/09/2009 | WO2009043457A2 Use of human hemokinin-1 and optionally oxytocin to treat diseases involving excessive angiogenesis |
| 04/09/2009 | WO2009043456A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043455A2 Therapeutic uses of angiogenin 108-122 and gluten exorphin a5 |
| 04/09/2009 | WO2009043454A2 Use of pacap-27 as a therapeutic agent |
| 04/09/2009 | WO2009043452A1 Use of rfrp, alone or in combination with neurokinin-b, as a therapeutic agent |
| 04/09/2009 | WO2009043451A2 Use of chorionic gonadotropin-beta (109-145) as a therapeutic agent |
| 04/09/2009 | WO2009043450A2 Use of neurotrophic factor for retinal cholinergic neurons (nfrcn) and chorionic gonadotropin-beta (109-145) as therapeutic agents |
| 04/09/2009 | WO2009043449A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043448A2 Neuromedin u-25 and neuromedin s as therapeutic agents |
| 04/09/2009 | WO2009043447A2 Use of a peptide as a therapeutic agent |